Slides and webcasts from ESMO Virtual Plenaries are open to all, ESMO Members and free ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- Start date
- 15 Jul 2021
- End date
- 16 Jul 2021
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Programme
Thursday, 15 July 2021
19:30-20:30 CEST
Welcome and introduction, Scientific background and context
Fabrice André, Gustave Roussy, Villejuif, France
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK
Critical analysis and perspectives
Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy
Discussion and Q&A (i)
Faculty and online audience
Friday, 16 July 2021
13:15-14:25 CEST (07:15 EDT / 19:15 SGT / 20:15 KST / 21:15 AEST)
Virtual Plenary Expert Insights: Webcast of 15 July presentations, Discussion and Q&A (ii)
Faculty and online audience:
Chair: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia
Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK
Giuseppe Curigliano, IEO - European Institute of Oncology, Milan, Italy
Lisa Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Yoon-Sim Yap, NCCS - National Cancer Centre Singapore
